estrone has been researched along with Bone Loss, Perimenopausal in 27 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum sex hormone binding globulin increased and leptin decreased with weight loss (P < 0." | 5.09 | Moderate energy restriction increases bone resorption in obese postmenopausal women. ( Chowdhury, HA; Heymsfield, SB; Pierson, RN; Ricci, TA; Shapses, SA; Stahl, T, 2001) |
| "We recruited 177 post-menopausal women to register hot flashes, vaginal dryness, depression, anxiety, sleep alterations, and serum hormones (FSH, LH, estrone, and estradiol)." | 3.72 | The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women. ( Malacara, JM; Martínez-Garza, S; Pérez-Luque, EL; Sánchez-Marín, FJ, 2004) |
| " We used intent-to-treat analysis (N = 224) and compliant analysis (>95%; N = 208) to assess circulating hormone concentrations, adverse events, and endometrial thickness (via transvaginal ultrasound)." | 2.80 | Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women. ( Alekel, DL; Beer, BS; Genschel, U; Hanson, LN; Hofmann, H; Koehler, KJ; Kurzer, MS; Peterson, CT; Van Loan, MD, 2015) |
| "Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0." | 2.70 | Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. ( Heshmati, HM; Khosla, S; Melton, LJ; O'Fallon, WM; Riggs, BL; Robins, SP, 2002) |
| "We randomly assigned 278 healthy, early postmenopausal women to receive either 2 mg 17beta-estradiol sequentially combined with 25 microg gestodene (group 2/25s), 2 mg estradiol sequentially combined with 50 microg gestodene (group 2/50s), 1 mg estradiol sequentially combined with 25 microg gestodene (group 1/25s), 1 mg estradiol continuously combined with 25 mg gestodene (group 1/25c), or placebo." | 2.69 | Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. ( Bjarnason, NH; Byrjalsen, I; Christiansen, C; Haarbo, J; Hassager, C, 2000) |
| "Biochemical parameters reflecting bone resorption [urinary calcium/creatinine (Ca/Cr) and hydroxyproline/creatinine (OH/Cr)] were related to serum estrogens [estrone (E1) and estradiol (E2)] in 262 healthy women including 158 patients receiving estrogen replacement therapy (ERT) for at least 6 months, 49 eugonadal women, and 55 untreated postmenopausal women." | 2.67 | Minimal levels of serum estradiol prevent postmenopausal bone loss. ( Albert, A; Deroisy, R; Franchimont, P; Gaspard, U; Reginster, JY; Sarlet, N, 1992) |
| "625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period." | 2.67 | Effect of estrone sulfate on postmenopausal bone loss. ( Baylink, DJ; Gallagher, JC; Genant, HK; Harris, ST; Herber, M; Steiger, P, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alekel, DL | 1 |
| Genschel, U | 1 |
| Koehler, KJ | 1 |
| Hofmann, H | 1 |
| Van Loan, MD | 1 |
| Beer, BS | 1 |
| Hanson, LN | 1 |
| Peterson, CT | 1 |
| Kurzer, MS | 1 |
| Riggs, BL | 3 |
| Khosla, S | 2 |
| Atkinson, EJ | 1 |
| Dunstan, CR | 1 |
| Melton, LJ | 2 |
| Gutteridge, DH | 1 |
| Holzherr, ML | 1 |
| Retallack, RW | 1 |
| Price, RI | 1 |
| Will, RK | 1 |
| Dhaliwal, SS | 1 |
| Faulkner, DL | 1 |
| Stewart, GO | 1 |
| Stuckey, BG | 1 |
| Prince, RL | 1 |
| Criddle, RA | 1 |
| Drury, PJ | 1 |
| Tran, L | 1 |
| Bhagat, CI | 1 |
| Kent, GN | 1 |
| Jamrozik, K | 1 |
| Muller, ME | 1 |
| Webber, CE | 1 |
| Adachi, JD | 1 |
| POLISHUK, Z | 1 |
| KLEINHAUSE, EM | 1 |
| Scariano, JK | 1 |
| Simplicio, SG | 1 |
| Montoya, GD | 1 |
| Garry, PJ | 1 |
| Baumgartner, RN | 1 |
| Malacara, JM | 1 |
| Pérez-Luque, EL | 1 |
| Martínez-Garza, S | 1 |
| Sánchez-Marín, FJ | 1 |
| Stanosz, S | 1 |
| Zochowska, E | 1 |
| Stanosz, M | 1 |
| Jassal, SK | 1 |
| Barrett-Connor, E | 1 |
| Edelstein, SL | 1 |
| Suzuki, N | 1 |
| Yano, T | 1 |
| Nakazawa, N | 1 |
| Yoshikawa, H | 1 |
| Taketani, Y | 1 |
| Mück, AO | 1 |
| Lippert, TH | 1 |
| Naessen, T | 1 |
| Berglund, L | 1 |
| Ulmsten, U | 1 |
| Dören, M | 1 |
| Lu, B | 1 |
| Qiu, M | 1 |
| Zheng, H | 2 |
| Bjarnason, NH | 1 |
| Byrjalsen, I | 1 |
| Hassager, C | 1 |
| Haarbo, J | 1 |
| Christiansen, C | 1 |
| Ricci, TA | 1 |
| Heymsfield, SB | 1 |
| Pierson, RN | 1 |
| Stahl, T | 1 |
| Chowdhury, HA | 1 |
| Shapses, SA | 1 |
| Downey, D | 1 |
| Spencer, SJ | 1 |
| Deghenghi, R | 1 |
| Jaffe, RB | 1 |
| Sun, L | 1 |
| Qiu, MC | 1 |
| Weng, LL | 1 |
| Liu, JS | 1 |
| Heshmati, HM | 1 |
| Robins, SP | 1 |
| O'Fallon, WM | 2 |
| Reginster, JY | 1 |
| Sarlet, N | 1 |
| Deroisy, R | 1 |
| Albert, A | 1 |
| Gaspard, U | 1 |
| Franchimont, P | 1 |
| Lufkin, EG | 1 |
| Wahner, HW | 1 |
| Hodgson, SF | 1 |
| Kotowicz, MA | 1 |
| Lane, AW | 1 |
| Judd, HL | 1 |
| Caplan, RH | 1 |
| Van Erpecum, KJ | 1 |
| Van Berge Henegouwen, GP | 1 |
| Verschoor, L | 1 |
| Stoelwinder, B | 1 |
| Willekens, FL | 1 |
| Harris, ST | 2 |
| Genant, HK | 2 |
| Baylink, DJ | 2 |
| Gallagher, JC | 2 |
| Karp, SK | 1 |
| McConnell, MA | 1 |
| Green, EM | 1 |
| Stoll, RW | 1 |
| Steiger, P | 1 |
| Herber, M | 1 |
| Rudy, DR | 1 |
| Li, XY | 1 |
| van Hemert, AM | 1 |
| Birkenhäger, JC | 1 |
| De Jong, FH | 1 |
| Vandenbroucke, JP | 1 |
| Valkenburg, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bone Response to Soy Isoflavones in Women[NCT00043745] | Phase 2 | 224 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for estrone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
[The value of laboratory studies for diagnosis of osteoporosis].
Topics: Aged; Calcium; Clinical Laboratory Techniques; Estradiol; Estrogen Replacement Therapy; Estrone; Fem | 1994 |
An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis.
Topics: Case-Control Studies; Cohort Studies; Estradiol; Estradiol Congeners; Estrogen Replacement Therapy; | 1999 |
13 trials available for estrone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women.
Topics: Aged; Double-Blind Method; Endometrium; Estradiol; Estrogens; Estrone; Female; Humans; Intention to | 2015 |
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Calcitriol; Drug Therapy, Combination; Estro | 2003 |
Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition.
Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Estrogen Replacement Therapy; Estrogens, | 2003 |
[Biochemical aspects of modified, transdermal replacement hormone therapy].
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Bone Density; Estriol; Estrogen Replacement | 2007 |
Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol.
Topics: Administration, Intravaginal; Aged; Aging; Alkaline Phosphatase; Analysis of Variance; Atrophy; Bone | 1997 |
Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss.
Topics: Bone Density; Climacteric; Collagen; Collagen Type I; Creatinine; Estradiol; Estrone; Female; Follic | 2000 |
Moderate energy restriction increases bone resorption in obese postmenopausal women.
Topics: Absorptiometry, Photon; Adipose Tissue; Body Composition; Bone Density; Bone Resorption; Diet, Reduc | 2001 |
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.
Topics: Aged; Aromatase Inhibitors; Bone Remodeling; Bone Resorption; Double-Blind Method; Enzyme Inhibitors | 2002 |
Minimal levels of serum estradiol prevent postmenopausal bone loss.
Topics: Analysis of Variance; Bone Resorption; Calcium; Creatinine; Estradiol; Estrogen Replacement Therapy; | 1992 |
Treatment of postmenopausal osteoporosis with transdermal estrogen.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Bone Density; Double-Blind Method; Drug Thera | 1992 |
Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Bile; Bile Acids and Salts; Biliary Tr | 1991 |
The effects of estrone (Ogen) on spinal bone density of postmenopausal women.
Topics: Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Endometrial Hyperplasia; Estron | 1991 |
Effect of estrone sulfate on postmenopausal bone loss.
Topics: Bone Density; Calcium Carbonate; Cholesterol; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1990 |
12 other studies available for estrone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency.
Topics: Aged; Bone Resorption; Estradiol; Estrone; Female; Glycoproteins; Gonadal Steroid Hormones; Humans; | 2003 |
Treatment of post-menopausal osteoporosis with estrone micro-crystal precipitates.
Topics: Estrogens; Estrone; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal | 1952 |
Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Dinucleotide Repeats; Estradiol; Estrogen Rec | 2004 |
The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women.
Topics: Anxiety; Bone Density; Cross-Sectional Studies; Depression; Educational Status; Estradiol; Estrogen | 2004 |
Low bioavailable testosterone levels predict future height loss in postmenopausal women.
Topics: Aged; Aged, 80 and over; Body Height; California; Cohort Studies; Estradiol; Estrone; Female; Humans | 1995 |
A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density.
Topics: Adipose Tissue; Aged; Body Mass Index; Bone Density; Estrone; Female; Humans; Middle Aged; Osteoporo | 1995 |
[Comparative study of tetracycline-estrone and estrone effects on bone histomorphometric parameters in ovariectomized rats].
Topics: Animals; Bone Density; Estrone; Female; Femur; Humans; Osteoporosis, Postmenopausal; Ovariectomy; Ra | 1998 |
Oral, water-soluble combined estrogen/calcium preparation for postmenopausal therapy.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Calcium; Chemistry, Pharmaceutical; Drug Administra | 2001 |
Effects of 2-[3-estrone-N-ethyl-piperazine-methyl]tetracycline (XW630) on osteoporosis in ovariectomized rats.
Topics: Animals; Estradiol; Estrogens, Conjugated (USP); Estrone; Female; Femur; Humans; Osteoporosis, Postm | 2000 |
Hormone replacement therapy. How to select the best preparation and regimen.
Topics: Cardiovascular Diseases; Climacteric; Contraindications; Estradiol; Estrogen Replacement Therapy; Es | 1990 |
[Relation of estrogen and bone loss in postmenopausal women].
Topics: Adult; Alkaline Phosphatase; Bone Density; Estradiol; Estrone; Female; Humans; Middle Aged; Osteopor | 1989 |
Sex hormone binding globulin in postmenopausal women: a predictor of osteoporosis superior to endogenous oestrogens.
Topics: Androstenedione; Body Height; Body Weight; Bone and Bones; Estradiol; Estrogens; Estrone; Female; Fr | 1989 |